Lori Hemrock
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Lori Hemrock has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Noha N. Soror
Internal Medicine, Western Reserve Health Education/Northeast Ohio Medical University (NEOMED), Warren, USA
4 shared publications - Parth Shah
Internal Medicine, Western Reserve Health Education/Northeast Ohio Medical University (NEOMED), Warren, USA
3 shared publications - Robert Bennett
Pathology, Steward Health Care, Warren, USA
3 shared publications - Gary Gibson
Internal Medicine, Steward Health Care, Warren, USA
2 shared publications - Biswaraj Tharu
Internal Medicine, Trumbull Regional Medical Center, Warren, USA
1 shared publication - Daniel Woredekal
Department of Medicine, Trumbull Regional Medical Center, Youngstown, USA
1 shared publication
Latest Publications
- Open Access
- 23 July 2021
- Published by Springer Nature in Cureus
- Vol. 13 (7)
A Rare Case of Primary Adenocarcinoma of the Eyelid: Case Presentation and Review of Literature
Primary mucinous adenocarcinoma (PMA) of the eyelid is a very rare malignancy with an incidence of 0.07 per million. Most cases are elderly males with an indolent course of local growth over months. We report a rare case of a 61-year-old gentleman with an aggressive course of PMA. The patient presented with a painless lower right eyelid swelling that developed over a four-month period. Incisional biopsy of the mass disclosed mucinous adenocarcinoma, positive for cytokeratin (CK)7 but negative for thyroid transcription factor 1, S100, and CK20 expression. Magnetic resonance imaging of the orbits revealed an enhancing infiltrative mass extending from the right lower eyelid to the medial canthus and posteriorly into the orbit, the right ethmoid sinuses, and extraconal fat within the orbit. Workup for metastatic disease including scans of chest, abdomen, and pelvis as well as positron emission tomography/computed tomography were negative for other masses. The patient underwent extensive surgery that included exenteration of the right orbit and cervical lymph node dissection followed by adjuvant radiation therapy and chemotherapy due to the extent of periorbital tumor invasion of contiguous tissues. Diagnosis of PMA is a clinical challenge, and immunohistochemistry is essential for diagnosis. To confirm it as a primary tumor, exclusion of metastasis from elsewhere is appropriate. Reported treatment modalities include Mohs micrographic surgery or excision with frozen section and safety margin. Exenteration of the orbit may be indicated depending on the extent of orbital invasion by the tumor. There is limited evidence to guide treatment and follow-up, with information consisting mostly of published case reports and case series.
- 23 July 2021
- Published by Springer Nature in Cureus
- Vol. 13 (7)
Open AccessA Rare Case of Primary Adenocarcinoma of the Eyelid: Case Presentation and Review of Literature
Primary mucinous adenocarcinoma (PMA) of the eyelid is a very rare malignancy with an incidence of 0.07 per million. Most cases are elderly males with an indolent course of local growth over months. We report a rare case of a 61-year-old gentleman with an aggressive course of PMA. The patient presented with a painless lower right eyelid swelling that developed over a four-month period. Incisional biopsy of the mass disclosed mucinous adenocarcinoma, positive for cytokeratin (CK)7 but negative for thyroid transcription factor 1, S100, and CK20 expression. Magnetic resonance imaging of the orbits revealed an enhancing infiltrative mass extending from the right lower eyelid to the medial canthus and posteriorly into the orbit, the right ethmoid sinuses, and extraconal fat within the orbit. Workup for metastatic disease including scans of chest, abdomen, and pelvis as well as positron emission tomography/computed tomography were negative for other masses. The patient underwent extensive surgery that included exenteration of the right orbit and cervical lymph node dissection followed by adjuvant radiation therapy and chemotherapy due to the extent of periorbital tumor invasion of contiguous tissues. Diagnosis of PMA is a clinical challenge, and immunohistochemistry is essential for diagnosis. To confirm it as a primary tumor, exclusion of metastasis from elsewhere is appropriate. Reported treatment modalities include Mohs micrographic surgery or excision with frozen section and safety margin. Exenteration of the orbit may be indicated depending on the extent of orbital invasion by the tumor. There is limited evidence to guide treatment and follow-up, with information consisting mostly of published case reports and case series.
- Open Access
- 11 May 2021
- Published by Springer Nature in Cureus
- Vol. 13 (5)
Primary Squamous Cell Carcinoma of the Thyroid: A Case Report and Literature Review About a Rare Entity
Primary squamous cell carcinoma of the thyroid (PSCCT) is a rare and aggressive neoplasm that accounts for less than 1% of all thyroid malignancies. Its incidence is higher in females in their fifth and sixth decades of life. The pathophysiology of PSCCT is still a subject of debate as squamous cells are generally absent in the thyroid gland under normal physiologic conditions. Immunohistochemistry is important for reaching a definite diagnosis as it helps to differentiate PSCCT from metastases from other primary sites. Clinically, PSCCT usually presents as a rapidly enlarging anterior neck mass. Surgical resection is the mainstay of treatment despite the lack of any standard guidelines for the same given the rarity of the disease. Adjuvant chemotherapy, radiotherapy, and targeted therapy continue to be of unclear benefit. We report a case of PSSCT in a male patient who presented with a rapidly enlarging neck mass.
- 11 May 2021
- Published by Springer Nature in Cureus
- Vol. 13 (5)
Open AccessPrimary Squamous Cell Carcinoma of the Thyroid: A Case Report and Literature Review About a Rare Entity
Primary squamous cell carcinoma of the thyroid (PSCCT) is a rare and aggressive neoplasm that accounts for less than 1% of all thyroid malignancies. Its incidence is higher in females in their fifth and sixth decades of life. The pathophysiology of PSCCT is still a subject of debate as squamous cells are generally absent in the thyroid gland under normal physiologic conditions. Immunohistochemistry is important for reaching a definite diagnosis as it helps to differentiate PSCCT from metastases from other primary sites. Clinically, PSCCT usually presents as a rapidly enlarging anterior neck mass. Surgical resection is the mainstay of treatment despite the lack of any standard guidelines for the same given the rarity of the disease. Adjuvant chemotherapy, radiotherapy, and targeted therapy continue to be of unclear benefit. We report a case of PSSCT in a male patient who presented with a rapidly enlarging neck mass.
- Open Access
- 31 January 2021
- Published by Springer Nature in Cureus
- Vol. 13 (1)
Brain Stem Encephalitis in a Patient With Recurrent Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor: Case Presentation and Review of the Literature
Immunotherapy with checkpoint inhibitors (CPIs) has revolutionized the management of advanced cancer including advanced small cell lung cancer (SCLC). Unfortunately, those agents are not without adverse effects. Immune imbalance through enhanced cellular immune response may result in impaired endogenous immunological tolerance mechanisms that can result in a wide spectrum of immunological side effects also known as immune-related adverse events (irAEs). Scarce data are currently available about neurological immune-related adverse events (neuro irAEs), mainly obtained from clinical trials, case reports, or small case series. Most reported cases presented with nonspecific symptoms. It is important to recognize and promptly treat neuro irAEs, as it may be serious and even potentially fatal. We present a rare case of nivolumab induced brain stem encephalitis in a patient with advanced SCLC presented 10 months after starting treatment with symptoms of nystagmus, gait disturbance, and blurry vision. Nivolumab was held and the patient was started on oral steroids with tapering dose. The patient’s symptoms gradually improved over a few weeks. Re-challenging with nivolumab six weeks later resulted in recurrence of symptoms and again the patient was prescribed oral steroids with tapering dose. She maintained response off treatment for six months. This case report is aimed to highlight the importance of clinically suspecting and promptly treating neurological irAE, when managing a patient with CPIs.
- 31 January 2021
- Published by Springer Nature in Cureus
- Vol. 13 (1)
Open AccessBrain Stem Encephalitis in a Patient With Recurrent Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor: Case Presentation and Review of the Literature
Immunotherapy with checkpoint inhibitors (CPIs) has revolutionized the management of advanced cancer including advanced small cell lung cancer (SCLC). Unfortunately, those agents are not without adverse effects. Immune imbalance through enhanced cellular immune response may result in impaired endogenous immunological tolerance mechanisms that can result in a wide spectrum of immunological side effects also known as immune-related adverse events (irAEs). Scarce data are currently available about neurological immune-related adverse events (neuro irAEs), mainly obtained from clinical trials, case reports, or small case series. Most reported cases presented with nonspecific symptoms. It is important to recognize and promptly treat neuro irAEs, as it may be serious and even potentially fatal. We present a rare case of nivolumab induced brain stem encephalitis in a patient with advanced SCLC presented 10 months after starting treatment with symptoms of nystagmus, gait disturbance, and blurry vision. Nivolumab was held and the patient was started on oral steroids with tapering dose. The patient’s symptoms gradually improved over a few weeks. Re-challenging with nivolumab six weeks later resulted in recurrence of symptoms and again the patient was prescribed oral steroids with tapering dose. She maintained response off treatment for six months. This case report is aimed to highlight the importance of clinically suspecting and promptly treating neurological irAE, when managing a patient with CPIs.
- Open Access
- 11 January 2021
- Published by Springer Nature in Cureus
- Vol. 13 (1)
Uterine Carcinosarcoma in a Young Female: Case Report and Literature Review
Uterine carcinosarcoma (USC) is a rare, aggressive primary neoplasm of the Uterus that represents less than 5% of all uterine malignancies. It usually affects older females in their seventh decade. USC disproportionally affects black women more and it has a worse prognosis than other endometrial carcinomas. We present a case of uterine carcinosarcoma in a young Caucasian female who presented with vague symptoms of nausea, vomiting, and severe iron deficiency anemia.
- 11 January 2021
- Published by Springer Nature in Cureus
- Vol. 13 (1)
Open AccessUterine Carcinosarcoma in a Young Female: Case Report and Literature Review
Uterine carcinosarcoma (USC) is a rare, aggressive primary neoplasm of the Uterus that represents less than 5% of all uterine malignancies. It usually affects older females in their seventh decade. USC disproportionally affects black women more and it has a worse prognosis than other endometrial carcinomas. We present a case of uterine carcinosarcoma in a young Caucasian female who presented with vague symptoms of nausea, vomiting, and severe iron deficiency anemia.